555 related articles for article (PubMed ID: 29635163)
21. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
Zugmaier G; Klinger M; Schmidt M; Subklewe M
Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
[TBL] [Abstract][Full Text] [Related]
22. Bispecific antibodies: design, therapy, perspectives.
Sedykh SE; Prinz VV; Buneva VN; Nevinsky GA
Drug Des Devel Ther; 2018; 12():195-208. PubMed ID: 29403265
[TBL] [Abstract][Full Text] [Related]
23. A review of blinatumomab, a novel immunotherapy.
Newman MJ; Benani DJ
J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
[TBL] [Abstract][Full Text] [Related]
24. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap.
Longhitano AP; Slavin MA; Harrison SJ; Teh BW
Blood Rev; 2021 Sep; 49():100810. PubMed ID: 33676765
[TBL] [Abstract][Full Text] [Related]
25. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
26. Targeting non-Hodgkin lymphoma with blinatumomab.
Sanders S; Stewart DA
Expert Opin Biol Ther; 2017 Aug; 17(8):1013-1017. PubMed ID: 28532177
[TBL] [Abstract][Full Text] [Related]
27. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
Stieglmaier J; Benjamin J; Nagorsen D
Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
[TBL] [Abstract][Full Text] [Related]
28. Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies.
Rogala B; Freyer CW; Ontiveros EP; Griffiths EA; Wang ES; Wetzler M
Expert Opin Biol Ther; 2015 Jun; 15(6):895-908. PubMed ID: 25985814
[TBL] [Abstract][Full Text] [Related]
29. Are BiTEs the "missing link" in cancer therapy?
Suryadevara CM; Gedeon PC; Sanchez-Perez L; Verla T; Alvarez-Breckenridge C; Choi BD; Fecci PE; Sampson JH
Oncoimmunology; 2015 Jun; 4(6):e1008339. PubMed ID: 26155413
[TBL] [Abstract][Full Text] [Related]
30. Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.
Klinger M; Benjamin J; Kischel R; Stienen S; Zugmaier G
Immunol Rev; 2016 Mar; 270(1):193-208. PubMed ID: 26864113
[TBL] [Abstract][Full Text] [Related]
31. Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting.
Han L; Xing H; Cao W; Song Y; Jiang Z; Yu J
Expert Opin Biol Ther; 2024 Apr; 24(4):221-223. PubMed ID: 38506624
[TBL] [Abstract][Full Text] [Related]
32. Bispecific antibodies for cancer therapy: A review.
Krishnamurthy A; Jimeno A
Pharmacol Ther; 2018 May; 185():122-134. PubMed ID: 29269044
[TBL] [Abstract][Full Text] [Related]
33. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
Schuster SJ
Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
[TBL] [Abstract][Full Text] [Related]
34. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
Dahl J; Mace M; Kantarjian H; Jabbour E
Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
[TBL] [Abstract][Full Text] [Related]
35. [Recent progress of bispecific antibody-based therapy for hematological malignancies].
Ochi T
Rinsho Ketsueki; 2022; 63(9):1298-1309. PubMed ID: 36198556
[TBL] [Abstract][Full Text] [Related]
36. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
Long M; Mims AS; Li Z
Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
[TBL] [Abstract][Full Text] [Related]
37. Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma.
Bukhari A; Lee ST
Expert Rev Hematol; 2019 Nov; 12(11):909-918. PubMed ID: 31583919
[No Abstract] [Full Text] [Related]
38. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
Wu J; Fu J; Zhang M; Liu D
J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
[TBL] [Abstract][Full Text] [Related]
39. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
40. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
